Evotec SE (EVO) Analyse boursière

Présentation de l'entreprise

Evotec SE operates globally as a specialized drug discovery and development entity with a physical presence in the United States, Germany, France, the United Kingdom, Switzerland, and other international markets. The company functions within the Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which focuses on creating proprietary or generic pharmaceutical solutions rather than large-scale commodity manufacturing. With a market capitalization of $963.68M and an annual revenue of $756.33M, the firm employs a workforce of 4788 individuals to execute its operational strategy. These financial figures indicate that Evotec maintains a mid-cap positioning within the pharmaceutical landscape, reflecting a balance between established operations and the capital-intensive nature of the specialty drug development sector.

Santé financière

The company reported a revenue of $756.33M over the trailing twelve months, yet it recorded a net income of $-158,980,000 and an EBITDA of $13,000. The substantial gap between the reported revenue and the negative net income reveals a cost structure characterized by high operating expenses that significantly erode profitability before taxes. Free cash flow stands at $-207,618,880, indicating that the company is currently burning cash, which limits its immediate financial flexibility and reliance on external capital markets or internal reserves. Profitability metrics are under pressure, evidenced by a gross margin of 10.8%, an operating margin of -26.6%, and a profit margin of -21.0%. The negative operating and profit margins suggest that overhead costs, likely driven by research and development expenditures, exceed gross profits from sales. On the balance sheet, total cash of $237.27M is insufficient to cover total debt of $484.62M, resulting in a debt-to-equity ratio of 60.57. This leverage profile indicates a highly leveraged balance sheet rather than a conservative one, as liabilities exceed liquid assets and equity. Liquidity for short-term obligations appears manageable given a current ratio of 2.12, which suggests the company holds more than double the current assets relative to its current liabilities. Return metrics further highlight the financial strain, with a return on equity of -18.0% and a return on assets of -2.7%. These negative return figures reveal that management is currently destroying value for shareholders and failing to generate returns on the capital base employed in the business.

Évaluation de la valorisation

Valuation multiples present a complex picture due to the company's lack of earnings, with a trailing P/E ratio of N/A and a forward P/E of -14.16. The negative forward P/E implies that the market prices in future earnings recovery but currently values the stock based on a multiple of negative expected earnings or alternative metrics. The price-to-book ratio is 1.03, indicating that the market is valuing the company at roughly equal to its net asset value, offering no significant premium over book value. Alternative valuation measures such as a price-to-sales ratio of 1.27 and an EV/EBITDA of 55790.93 suggest that the stock is priced on revenue rather than profitability, as the EV/EBITDA multiple is exceptionally high due to minimal EBITDA. The stock has traded between a 52-week high of $4.80 and a 52-week low of $2.31. Without the current price explicitly listed in the facts, the valuation context relies on the breadth of this range, where the price-to-sales multiple anchors the valuation to top-line performance rather than earnings power. The beta value of 1.24 indicates that the stock's price volatility is 24% higher than the broader market, reflecting the inherent risks associated with the drug discovery business model.

Growth & Income

Revenue growth year-over-year stands at -11.4%, while earnings growth is N/A. The decline in revenue indicates a contraction in the top line, and the absence of positive earnings growth implies that the company is not currently expanding profitability. Since earnings growth is unavailable due to negative net income, the comparison between earnings and revenue growth rates is not applicable in a traditional growth sense, as the firm is not generating profits to scale. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This lack of dividend distribution means that the company reinvests its limited earnings or burns cash to fund its research and development initiatives rather than returning capital to shareholders. Consequently, the overall growth and income profile is characterized by revenue contraction and a complete absence of dividend income, relying entirely on future product approvals or partnerships to reverse the current financial trajectory.